

# Bruno Quesnel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5536492/publications.pdf>

Version: 2024-02-01

250  
papers

12,049  
citations

31976

53  
h-index

30922

102  
g-index

255  
all docs

255  
docs citations

255  
times ranked

13022  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pairing cells of different sizes in a microfluidic device for immunological synapse monitoring. <i>Lab on A Chip</i> , 2022, 22, 908-920.	6.0	3
2	Put in a $\text{Ca}^{2+}$ -to Acute Myeloid Leukemia. <i>Cells</i> , 2022, 11, 543.	4.1	3
3	TRPC3 shapes the ER-mitochondria $\text{Ca}^{2+}$ transfer characterizing tumour-promoting senescence. <i>Nature Communications</i> , 2022, 13, 956.	12.8	29
4	Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2022, 101, 1321-1331.	1.8	4
5	Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114343.	5.5	11
6	p65/RelA NF $\kappa$ B fragments generated by RIPK3 activity regulate tumorigenicity, cell metabolism, and stemness characteristics. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 543-556.	2.6	3
7	Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity. <i>PLoS ONE</i> , 2022, 17, e0267508.	2.5	0
8	Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5555.	4.1	5
9	Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents. <i>Leukemia Research</i> , 2022, 118, 106871.	0.8	0
10	Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3368.	3.7	7
11	Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy. <i>EJHaem</i> , 2021, 2, 196-210.	1.0	1
12	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1162.	2.4	3
13	Acute Myeloid Leukemia: Is It T Time?. <i>Cancers</i> , 2021, 13, 2385.	3.7	8
14	Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myéloblastoses (GFM). <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1583.	1.6	169
15	Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. <i>Cancers</i> , 2021, 13, 3034.	3.7	56
16	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. <i>Cancer Medicine</i> , 2021, 10, 6336-6343.	2.8	6
17	Expanded Access Program: Evaluating Safety of Erythrocytes Encapsulating L-Asparaginase in Combination with Polychemotherapy in Patients Under 55 Years Old with Acute Lymphoblastic Leukaemia (ALL) at Risk to Receive Other Formulations of Asparaginase. <i>Blood</i> , 2021, 138, 1214-1214.	1.4	2
18	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 246-246.	1.4	21

#	ARTICLE	IF	CITATIONS
19	ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. <i>Molecular Metabolism</i> , 2021, 55, 101410.	6.5	3
20	Modulation of the Gal-9/TIM-3 Immune Checkpoint with Î±-Lactose. Does Anomery of Lactose Matter?. <i>Cancers</i> , 2021, 13, 6365.	3.7	7
21	Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2021, 13, 6353.	3.7	3
22	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2020, 382, 140-151.	27.0	335
23	Familial myeloid malignancies with germline TET2 mutation. <i>Leukemia</i> , 2020, 34, 1450-1453.	7.2	36
24	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. <i>Cancers</i> , 2020, 12, 1992.	3.7	24
25	Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size. <i>Leukemia Research Reports</i> , 2020, 13, 100202.	0.4	6
26	Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion Abilities. <i>Stem Cells and Development</i> , 2020, 29, 919-928.	2.1	5
27	Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. <i>NAR Cancer</i> , 2020, 2, zcaa002.	3.1	142
28	Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2230-2233.	7.2	1
29	Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST). <i>Bio-protocol</i> , 2020, 10, e3574.	0.4	10
30	Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 781-788.	2.5	18
31	CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. <i>Cancer Medicine</i> , 2019, 8, 1279-1288.	2.8	27
32	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. <i>Blood</i> , 2019, 134, 2414-2416.	1.4	14
33	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
34	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory. <i>American Journal of Hematology</i> , 2019, 94, E24-E27.	4.1	5
35	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélocytoses (GFM). <i>Blood</i> , 2019, 134, 677-677.	1.4	62
36	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. <i>Blood</i> , 2019, 134, 853-853.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Targeting MYC in multiple myeloma. <i>Leukemia</i> , 2018, 32, 1295-1306.	7.2	89
38	Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. <i>Cell Death and Disease</i> , 2018, 9, 325.	6.3	71
39	Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	7
40	CAR T-cells: A John von Neumann legacy?. <i>Current Research in Translational Medicine</i> , 2018, 66, 35-36.	1.8	13
41	Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology. <i>BMC Cancer</i> , 2018, 18, 1219.	2.6	11
42	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2018, 8, 665.	2.8	47
43	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2018, 132, 1-1.	1.4	57
44	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. <i>Blood</i> , 2018, 132, 467-467.	1.4	9
45	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 539-543.	2.4	30
46	Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 85, 166-174.	2.8	10
47	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1700178.	6.7	9
48	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	53
49	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. <i>Blood</i> , 2017, 130, 832-835.	1.4	55
50	Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity. <i>Immunology Letters</i> , 2017, 192, 27-34.	2.5	1
51	<i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2017, 23, 6325-6335.	7.0	64
52	Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes. <i>Current Research in Translational Medicine</i> , 2017, 65, 77-81.	1.8	7
53	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 555-564.	7.2	34
54	PD-1/PD-L1 binding studies using microscale thermophoresis. <i>Scientific Reports</i> , 2017, 7, 17623.	3.3	56

#	ARTICLE	IF	CITATIONS
55	Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial. <i>Blood</i> , 2017, 130, 889-889.	1.4	25
56	Role of IRF4 in resistance to immunomodulatory (IMiD) compounds <sup>®</sup> in Waldenström's macroglobulinemia. <i>Oncotarget</i> , 2017, 8, 112917-112927.	1.8	5
57	<i>BACH2</i> promotes indolent clinical presentation in Waldenström macroglobulinemia. <i>Oncotarget</i> , 2017, 8, 57451-57459.	1.8	2
58	GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation. <i>Biochemical and Biophysical Research Communications</i> , 2016, 478, 513-520.	2.1	16
59	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016, 7, 10767.	12.8	177
60	Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells. <i>Scientific Reports</i> , 2016, 6, 30405.	3.3	25
61	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e186-e195.	4.6	359
62	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. <i>Leukemia</i> , 2016, 30, 1416-1418.	7.2	16
63	Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2016, 22, 1480-1488.	7.0	102
64	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2016, 55, 397-405.	3.5	72
65	De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory. <i>Blood</i> , 2016, 128, 4013-4013.	1.4	4
66	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 62377-62385.	1.8	20
67	Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. <i>Oncotarget</i> , 2016, 7, 39473-39485.	1.8	58
68	Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia. <i>European Journal of Immunology</i> , 2015, 45, 396-406.	2.9	21
69	B7-H3 protein expression in acute myeloid leukemia. <i>Cancer Medicine</i> , 2015, 4, 1879-1883.	2.8	32
70	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 3618-3626.	1.4	197
71	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. <i>Leukemia Research</i> , 2015, 39, 501-504.	0.8	46
72	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. <i>Leukemia Research</i> , 2015, 39, 1443-1447.	0.8	9

#	ARTICLE	IF	CITATIONS
73	CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. <i>Cancer Research</i> , 2015, 75, 3902-3911.	0.9	36
74	Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650). <i>Blood</i> , 2015, 126, 4877-4877.	1.4	1
75	<i>IDH1/2</i>but not<i>DNMT3A</i> mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. <i>Oncotarget</i> , 2015, 6, 42345-42353.	1.8	92
76	Abstract 3216: Immunogenicity and genomic profiling reveal sub-clonal diversity of a murine acute myeloid leukemia (AML) cell line. , 2015, , .		0
77	Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group. <i>Blood</i> , 2015, 126, 2568-2568.	1.4	0
78	RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. <i>Cell Death and Disease</i> , 2014, 5, e1384-e1384.	6.3	105
79	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. <i>European Journal of Cancer</i> , 2014, 50, 196.	2.8	12
80	Outcomes in <sc>RBC</sc> transfusionâ€dependent patients with <sc>L</sc>owâ€<sc>I</sc>ntermediateâ€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <sc>MDS</sc>â€004 study. <i>European Journal of Haematology</i> , 2014, 93, 429-438.	2.2	32
81	<i>MYD</i>88<i> L265P mutation contributes to the diagnosis of Bing Neel syndrome. <i>British Journal of Haematology</i> , 2014, 167, 506-513.	2.5	71
82	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. <i>American Journal of Hematology</i> , 2014, 89, 410-416.	4.1	91
83	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. <i>Cancer Research</i> , 2014, 74, CT231-CT231.	0.9	23
84	Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis. <i>Blood</i> , 2014, 124, 1083-1083.	1.4	1
85	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. <i>Blood</i> , 2014, 124, 117-117.	1.4	27
86	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. <i>Blood</i> , 2014, 124, 2327-2327.	1.4	1
87	Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacitidine (AZA). <i>Blood</i> , 2014, 124, 482-482.	1.4	2
88	Abstract 1342: RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. , 2014, , .		0
89	Epidemiology of Adults AML in Nord-Pas De Calais and Picardy. <i>Blood</i> , 2014, 124, 2281-2281.	1.4	0
90	Monitoring of Wilmsâ€™ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1265-1265.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	1.4	12
92	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leukemia Research, 2013, 37, 637-640.	0.8	45
93	Tumor Dormancy: Long-Term Survival in a Hostile Environment. Advances in Experimental Medicine and Biology, 2013, 734, 181-200.	1.6	12
94	Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leukemia Research, 2013, 37, 573-579.	0.8	29
95	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	1.6	68
96	Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology, 2013, 88, 556-559.	4.1	30
97	The PI3K/AKT Signaling Pathway Controls the Quiescence of the Low-Rhodamine123-Retention Cell Compartment Enriched for Melanoma Stem Cell Activity. Stem Cells, 2013, 31, 641-651.	3.2	57
98	Outcome of older patients with acute myeloid leukemia in first relapse. American Journal of Hematology, 2013, 88, 758-764.	4.1	49
99	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	4.1	45
100	Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. European Journal of Haematology, 2013, 91, 315-321.	2.2	28
101	MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 2013, 121, 4504-4511.	1.4	214
102	Linezolid induces ring sideroblasts. Haematologica, 2013, 98, e138-e140.	3.5	21
103	The B7-H3 Protein In Acute Myeloid Leukemia. Blood, 2013, 122, 2620-2620.	1.4	1
104	Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML). Blood, 2013, 122, 2796-2796.	1.4	4
105	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€“ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. Blood, 2013, 122, 495-495.	1.4	0
106	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. Blood, 2013, 122, 2753-2753.	1.4	0
107	AML At First Relapse: A Real Life Picture. Blood, 2013, 122, 3895-3895.	1.4	0
108	Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leukemia and Lymphoma, 2012, 53, 1068-1076.	1.3	50

#	ARTICLE	IF	CITATIONS
109	GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells. <i>Oncogene</i> , 2012, 31, 1419-1430.	5.9	40
110	Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. <i>Blood</i> , 2012, 119, 6172-6173.	1.4	33
111	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. <i>Blood</i> , 2012, 120, 5084-5085.	1.4	50
112	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. <i>Leukemia Research</i> , 2012, 36, 1112-1118.	0.8	9
113	Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. <i>Leukemia Research</i> , 2012, 36, 1330-1333.	0.8	9
114	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. <i>British Journal of Haematology</i> , 2012, 157, 764-766.	2.5	49
115	MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2012, 120, 1307-1307.	1.4	2
116	Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM). <i>Blood</i> , 2012, 120, 297-297.	1.4	2
117	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. <i>Blood</i> , 2012, 120, 422-422.	1.4	3
118	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 1697-1697.	1.4	0
119	B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2012, 120, 1288-1288.	1.4	0
120	Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification. <i>Blood</i> , 2012, 120, 3843-3843.	1.4	0
121	Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells. <i>PLoS ONE</i> , 2011, 6, e21924.	2.5	49
122	Repression of the RHOH gene by JunD. <i>Biochemical Journal</i> , 2011, 437, 75-88.	3.7	8
123	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. <i>Blood</i> , 2011, 118, 3765-3776.	1.4	424
124	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. <i>Blood</i> , 2011, 117, 403-411.	1.4	348
125	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. <i>Blood</i> , 2011, 118, 1754-1762.	1.4	52
126	Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. <i>Leukemia</i> , 2011, 25, 1207-1209.	7.2	35



#	ARTICLE	IF	CITATIONS
127	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. <i>Leukemia</i> , 2011, 25, 1147-1152.	7.2	430
128	Synthesis and biological evaluation of phenstatin metabolites. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6042-6054.	3.0	28
129	A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. <i>Molecular Cancer</i> , 2011, 10, 105.	19.2	9
130	Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor-like state. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 1277-1285.	2.6	14
131	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. <i>Leukemia Research</i> , 2011, 35, 448-458.	0.8	17
132	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 3322-3327.	1.6	421
133	Acute Myocarditis Induced by Hypomethylating Agents. <i>Journal of Clinical Oncology</i> , 2011, 29, e411-e412.	1.6	12
134	Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. <i>Blood</i> , 2011, 118, 972-972.	1.4	1
135	Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA). <i>Blood</i> , 2011, 118, 253-253.	1.4	1
136	Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. <i>Blood</i> , 2010, 115, 78-88.	1.4	44
137	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. <i>Haematologica</i> , 2010, 95, 892-899.	3.5	18
138	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. <i>Blood</i> , 2010, 116, 1132-1135.	1.4	121
139	In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1839-1849.	4.2	143
140	A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. <i>Experimental Hematology</i> , 2010, 38, 124-131.e4.	0.4	34
141	Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. <i>Gene Therapy</i> , 2010, 17, 880-891.	4.5	19
142	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 1094-1096.	7.2	225
143	Dormance tumorale: quiescence ou équilibre?. <i>Hematologie</i> , 2010, 16, 355-362.	0.0	0
144	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. <i>Leukemia and Lymphoma</i> , 2010, 51, 1668-1677.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Activity of Ladanein on Leukemia Cell Lines and Its Occurrence in <i>Marrubium vulgare</i> . <i>Planta Medica</i> , 2010, 76, 86-87.	1.3	27
146	Humulane and Germacrane Sesquiterpenes from <i>Ferula lycia</i> . <i>Journal of Natural Products</i> , 2010, 73, 780-783.	3.0	10
147	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 3717-3723.	1.6	189
148	Antifungal and Cytotoxic Activity of Withanolides from <i>Acnistus arborescens</i> . <i>Journal of Natural Products</i> , 2010, 73, 1313-1317.	3.0	24
149	Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 3735-3742.	1.4	141
150	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). <i>Blood</i> , 2010, 116, 2183-2183.	1.4	13
151	FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 232-232.	1.4	3
152	Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML. <i>Blood</i> , 2010, 116, 3997-3997.	1.4	3
153	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. <i>Blood</i> , 2010, 116, 439-439.	1.4	10
154	Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group. <i>Blood</i> , 2010, 116, 505-505.	1.4	3
155	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010, 116, 2171-2171.	1.4	0
156	AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM). <i>Blood</i> , 2010, 116, 2911-2911.	1.4	0
157	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. <i>Blood</i> , 2010, 116, 4171-4171.	1.4	0
158	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. <i>Blood</i> , 2010, 116, 3996-3996.	1.4	0
159	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009, 94, 1676-1681.	3.5	234
160	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 4747-4753.	1.6	123
161	Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 547-550.	0.8	18
162	Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN- $\gamma$ . <i>Leukemia Research</i> , 2009, 33, 490-494.	0.8	91

#	ARTICLE	IF	CITATIONS
163	Methyltransferases in myelodysplastic syndromes: Guilty or not guilty?. <i>Leukemia Research</i> , 2009, 33, 601-602.	0.8	2
164	Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. <i>Atherosclerosis</i> , 2009, 204, e4-e14.	0.8	40
165	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009, 114, 3285-3291.	1.4	264
166	Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 1054-1054.	1.4	5
167	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 163-163.	1.4	4
168	Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 1773-1773.	1.4	3
169	Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 843-843.	1.4	13
170	Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 3820-3820.	1.4	0
171	Activity of elaeoichytrin A from <i>Ferula elaeoichytris</i> on leukemia cell lines. <i>Phytochemistry</i> , 2008, 69, 2979-2983.	2.9	40
172	Tumor dormancy and immunoescape. <i>Apmis</i> , 2008, 116, 685-694.	2.0	86
173	Dormant tumor cells as a therapeutic target?. <i>Cancer Letters</i> , 2008, 267, 10-17.	7.2	38
174	BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. <i>Leukemia</i> , 2008, 22, 791-799.	7.2	41
175	220 ACETAMINOPHEN THERAPEUTIC MISADVENTURE: A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2008, 48, S91.	3.7	1
176	Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM. <i>Blood</i> , 2008, 112, 2672-2672.	1.4	2
177	Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program. <i>Blood</i> , 2008, 112, 2682-2682.	1.4	3
178	Long-Term Survival Analysis in Older Patients with AML Treated Intensively: Positive Impact of Idarubicin in a Cure Fraction Estimation Model.. <i>Blood</i> , 2008, 112, 960-960.	1.4	0
179	Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup. <i>Blood</i> , 2008, 112, 553-553.	1.4	1
180	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 787-792.	1.6	239

#	ARTICLE	IF	CITATIONS
181	Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1. <i>Cancer Research</i> , 2007, 67, 4491-4498.	0.9	46
182	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN- $\gamma$ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. <i>Blood</i> , 2007, 110, 296-304.	1.4	546
183	MEK inhibitor: the MM magic bullet?. <i>Blood</i> , 2007, 110, 1402-1403.	1.4	4
184	Effect of priming with granulocyte macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. <i>Leukemia</i> , 2007, 21, 453-461.	7.2	74
185	Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. <i>Leukemia</i> , 2007, 21, 2376-2377.	7.2	13
186	Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.. <i>Blood</i> , 2007, 110, 249-249.	1.4	41
187	Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.. <i>Blood</i> , 2007, 110, 1849-1849.	1.4	0
188	Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?. <i>Expert Review of Vaccines</i> , 2006, 5, 773-781.	4.4	10
189	In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. <i>Journal of Obstetrics and Gynaecology Research</i> , 2006, 32, 449-453.	1.3	9
190	Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Leukemia</i> , 2006, 20, 35-41.	7.2	149
191	Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). <i>Leukemia</i> , 2006, 20, 965-970.	7.2	340
192	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. <i>Leukemia</i> , 2006, 20, 2067-2070.	7.2	64
193	Methylation and myelodysplastic syndromes: When and where?. <i>Leukemia Research</i> , 2006, 30, 1327-1329.	0.8	5
194	RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.. <i>Blood</i> , 2006, 108, 2661-2661.	1.4	1
195	Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.. <i>Blood</i> , 2006, 108, 2666-2666.	1.4	4
196	An 18-case outbreak of drug-resistant <i>Pseudomonas aeruginosa</i> bacteriemia in hematology patients. <i>Haematologica</i> , 2006, 91, 1134-8.	3.5	16
197	NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. <i>Blood</i> , 2005, 105, 2428-2435.	1.4	112
198	Multiple myeloma: all roads lead to cyclin D. <i>Blood</i> , 2005, 106, 1-2.	1.4	13

#	ARTICLE	IF	CITATIONS
199	Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. <i>Leukemia</i> , 2005, 19, 792-798.	7.2	108
200	Modelling a regional reorganization of cardiovascular surgery provision. <i>Health and Place</i> , 2005, 11, 283-292.	3.3	4
201	Induction of leukemia-specific CD8+ cytotoxic t cells with autologous myeloid leukemic cells matured with a fiber-modified adenovirus encoding TNF- $\alpha$ . <i>Molecular Therapy</i> , 2005, 11, 950-959.	8.2	8
202	No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study.. <i>Blood</i> , 2005, 106, 15-15.	1.4	16
203	Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.. <i>Blood</i> , 2005, 106, 1862-1862.	1.4	0
204	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2481-2484.	1.3	11
205	A case of refractory anemia with 17p <sup>+</sup> syndrome following azathioprine treatment for heart transplantation. <i>Leukemia</i> , 2004, 18, 878-878.	7.2	8
206	Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. <i>Leukemia</i> , 2004, 18, 1223-1230.	7.2	54
207	Efficient generation of antileukemic autologous T cells by short-term culture and $\gamma$ -irradiation of myeloid leukemic cells. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 793-8.	4.2	8
208	Short-term culture of myeloid leukemic cells allows efficient transduction by adenoviral vectors. <i>Journal of Gene Medicine</i> , 2004, 6, 751-759.	2.8	7
209	In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. <i>Blood</i> , 2004, 104, 2124-2133.	1.4	156
210	Three new cases of non-Hodgkin lymphoma with t(9;14)(p13;q32). <i>Cancer Genetics and Cytogenetics</i> , 2003, 145, 65-69.	1.0	17
211	Chemotherapy increases transgene expression in leukemic cells. <i>Journal of Gene Medicine</i> , 2003, 5, 852-859.	2.8	1
212	$\beta$ -Irradiation enhances transgene expression in leukemic cells. <i>Gene Therapy</i> , 2003, 10, 227-233.	4.5	18
213	SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. <i>Leukemia</i> , 2003, 17, 1678-1679.	7.2	20
214	Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. <i>Haematologica</i> , 2003, 88, 476-8.	3.5	24
215	Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities. <i>Leukemia and Lymphoma</i> , 2002, 43, 1819-1822.	1.3	7
216	Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2472-2479.	1.6	194

#	ARTICLE	IF	CITATIONS
217	p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2002, 99, 2620-2623.	1.4	27
218	TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. <i>Annales De G�n�r�tique</i> , 2002, 45, 165-168.	0.4	2
219	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. <i>Bone Marrow Transplantation</i> , 2002, 30, 229-234.	2.4	15
220	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. <i>Leukemia</i> , 2002, 16, 1637-1644.	7.2	45
221	Systemic injection of GM-CSF increases survival in a murine model of acute leukemia. <i>Haematologica</i> , 2002, 87, ELT13.	3.5	0
222	Pathologic and Clinical Features of 77 Hodgkin's Lymphoma Patients Treated in a Lymphoma Protocol (LNH87). <i>American Journal of Surgical Pathology</i> , 2001, 25, 297-306.	3.7	37
223	p16 INK4a and p15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2001, 98, 244-246.	1.4	77
224	Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients. <i>Annals of Oncology</i> , 2001, 12, 1749-1755.	1.2	14
225	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. <i>Leukemia</i> , 2001, 15, 1054-1059.	7.2	8
226	Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients. <i>The Hematology Journal</i> , 2001, 2, 81-86.	1.4	5
227	$\beta$ -Ray irradiation induces B7.1 expression in myeloid leukaemic cells. <i>British Journal of Haematology</i> , 2000, 108, 825-831.	2.5	57
228	Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. <i>Gene Therapy</i> , 2000, 7, 1312-1316.	4.5	42
229	Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. <i>Bone Marrow Transplantation</i> , 2000, 25, 251-256.	2.4	43
230	Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. <i>Groupe d'Etude des Lymphomes de l'Adulte. Haematologica</i> , 2000, 85, 502-7.	3.5	13
231	Transduction of Bone Marrow Cells by the AdZ.F(pK7) Modified Adenovirus Demonstrates Preferential Gene Transfer in Myeloma Cells. <i>Human Gene Therapy</i> , 1999, 10, 2709-2717.	2.7	42
232	P15 <sup>INK4b</sup> Gene Methylation and Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 1999, 35, 437-443.	1.3	51
233	Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. <i>Gene Therapy</i> , 1999, 6, 314-320.	4.5	57
234	Correspondence. <i>Leukemia Research</i> , 1999, 23, 415-416.	0.8	17

#	ARTICLE	IF	CITATIONS
235	A NEW CASE OF THERAPY-RELATED ACUTE MYELOID LEUKAEMIA WITH t(8;16)(p11;p13). British Journal of Haematology, 1998, 100, 801-802.	2.5	2
236	Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression. Blood, 1998, 91, 2985-2990.	1.4	337
237	Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 1998, 91, 2985-90.	1.4	96
238	p16 <sup>ink4a</sup> Gene and Hematological Malignancies. Leukemia and Lymphoma, 1996, 22, 11-24.	1.3	26
239	Transfer of p16 inka /CDKN2 gene in leukaemic cell lines inhibits cell proliferation. British Journal of Haematology, 1996, 95, 291-298.	2.5	22
240	Analysis of p16 gene deletion and point mutation in breast carcinoma. British Journal of Cancer, 1995, 72, 351-353.	6.4	36
241	<i>c-mpl</i> Expression in Hematologic Disorders. Leukemia and Lymphoma, 1995, 17, 19-26.	1.3	19
242	The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases. Leukemia and Lymphoma, 1995, 18, 497-503.	1.3	30
243	Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. British Journal of Haematology, 1994, 87, 61-67.	2.5	38
244	Over-expression of the MDM2 gene is found in some cases of haematological malignancies. British Journal of Haematology, 1994, 88, 415-418.	2.5	60
245	MDM2 gene amplification in human breast cancer. European Journal of Cancer, 1994, 30, 982-984.	2.8	53
246	Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 1994, 8, 1342-9.	7.2	61
247	Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1994, 8, 878-80.	7.2	12
248	Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature.. Journal of Clinical Oncology, 1993, 11, 2370-2379.	1.6	173
249	Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia, 1993, 7, 1888-90.	7.2	18
250	Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia, 1993, 7, 1071.	7.2	8